BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 26482385)

  • 21. Testosterone replacement therapy and the risk of prostate cancer. Is there a link?
    Barqawi A; Crawford ED
    Int J Impot Res; 2006; 18(4):323-8. PubMed ID: 16281043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors.
    Hackett G; Cole N; Mulay A; Strange RC; Ramachandran S
    BJU Int; 2019 Mar; 123(3):519-529. PubMed ID: 30216622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone treatment in the aging male: myth or reality?
    Nigro N; Christ-Crain M
    Swiss Med Wkly; 2012; 142():w13539. PubMed ID: 22430839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late-life onset hypogonadism: a review.
    Bassil N; Morley JE
    Clin Geriatr Med; 2010 May; 26(2):197-222. PubMed ID: 20497841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Testosterone therapy of men with type 2 diabetes mellitus - a randomized, double-blinded, placebo-controlled study.
    Magnussen LV
    Dan Med J; 2017 Jul; 64(7):. PubMed ID: 28673384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes.
    Muraleedharan V; Marsh H; Kapoor D; Channer KS; Jones TH
    Eur J Endocrinol; 2013 Dec; 169(6):725-33. PubMed ID: 23999642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controversies regarding the cardiovascular effects of testosterone replacement therapy in older men.
    Chrysant SG
    Drugs Today (Barc); 2018 Jan; 54(1):25-34. PubMed ID: 29569659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study.
    Wallis CJ; Lo K; Lee Y; Krakowsky Y; Garbens A; Satkunasivam R; Herschorn S; Kodama RT; Cheung P; Narod SA; Nam RK
    Lancet Diabetes Endocrinol; 2016 Jun; 4(6):498-506. PubMed ID: 27165609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone and the heart.
    Hackett G
    Int J Clin Pract; 2012 Jul; 66(7):648-55. PubMed ID: 22698417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
    Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
    Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Testosterone replacement therapy and cardiovascular risk].
    Corona G; Dicuio M; Rastrelli G; Sforza A; Maggi M
    G Ital Cardiol (Rome); 2017 Nov; 18(11):745-753. PubMed ID: 29105668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testosterone replacement therapy.
    Barbonetti A; D'Andrea S; Francavilla S
    Andrology; 2020 Nov; 8(6):1551-1566. PubMed ID: 32068334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency.
    Cheetham TC; An J; Jacobsen SJ; Niu F; Sidney S; Quesenberry CP; VanDenEeden SK
    JAMA Intern Med; 2017 Apr; 177(4):491-499. PubMed ID: 28241244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on Testosterone Replacement Therapy in Hypogonadal Men.
    Leung KM; Alrabeeah K; Carrier S
    Curr Urol Rep; 2015 Aug; 16(8):57. PubMed ID: 26077352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.
    Kaplan AL; Lenis AT; Shah A; Rajfer J; Hu JC
    J Sex Med; 2015 Feb; 12(2):374-80. PubMed ID: 25496237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EMAS position statement: Testosterone replacement therapy in the aging male‏.
    Dimopoulou C; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; van der Schouw YT; Senturk LM; Simonsini T; Stevenson JC; Stute P; Goulis DG
    Maturitas; 2016 Feb; 84():94-9. PubMed ID: 26614257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypogonadism in the man with erectile dysfunction: what to look for and when to treat.
    Lazarou S; Morgentaler A
    Curr Urol Rep; 2005 Nov; 6(6):476-81. PubMed ID: 16238923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testosterone replacement therapy: who to evaluate, what to use, how to follow, and who is at risk?
    Afiadata A; Ellsworth P
    Hosp Pract (1995); 2014 Dec; 42(5):69-82. PubMed ID: 25485919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
    Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
    Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.